AGENT FOR LOW-METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely nephrology, and may be used for administering ibandronate as an agent for low-metabolic bone disease in the patients suffering chronic renal insufficiency (CRI).;EFFECT: invention provides preventing developing incurable adynamic bone disease and transforming the low-metabolic bone disease into the high-metabolic bone disease thereby reducing the risks of fractures and a cardiovascular pathology, increasing the survival rate in the CRI patients.;2 tbl, 2 ex